Acute Myeloid Leukemia Induction with Cladribine: Outcomes by Age and Leukemia Risk
(Source: Leukemia Research)
Source: Leukemia Research - March 6, 2018 Category: Hematology Authors: Martin W. Schoen, Susan K. Woelich, James T. Braun, Dhinesh V. Reddy, Mark J. Fesler, Paul J. Petruska, Carl E. Freter, Jack M. Lionberger Tags: Research paper Source Type: research
RETRACTED: Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). (Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Chunxia Liu, Hulai Wei, Xiaojian Yao, Bei Liu, Yaming Xi, Li Zhao Source Type: research
No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in the pediatric population. Approximately 3000 children in the United States are diagnosed with ALL every year [1]. The survival rate of pediatric ALL has increased from less than 10% to 90% during the past four decades, due to the improvements in the efficacy of multiagent chemotherapy and stratification of treatment intensity [1]. (Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Qingkai Dai, Xiaojuan Liu, Hui Yang, Siqi Guo, Yuefang Wang, Luyun Peng, Lei Ye, Lan Chen, Chunqi Lai, Qi Chen, Ge Zhang, Yongmei Jiang Tags: Research paper Source Type: research
An autologous tumor vaccine for CLL
Chronic lymphocytic leukemia (CLL) is a disease characterized by the accumulation of long-lived B cells which usually express CD19, CD20, CD23 and CD5 on their cell surface. Such B cells expressing novel tumor antigens could be potential targets of immune cells [1]. The graft versus leukemia (GVL) effect after allogeneic stem cell transplantation was the first indication that CLL cells might indeed be subject to attack by immune cells [2]. It was also found that in CLL patients disease often went into remission after viral infections [3] or treatment with immunomodulatory cytokines [4]. (Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Fang Zhu, Ismat Khatri, David Spaner, Reginald M. Gorczynski Source Type: research
Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance
(Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Chunxia Liu, Hulai Wei, Xiaojian Yao, Bei Liu, Yaming Xi, Li Zhao Tags: Research paper Source Type: research
No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia
(Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Qingkai Dai, Xiaojuan Liu, Hui Yang, Siqi Guo, Yuefang Wang, Luyun Peng, Lei Ye, Lan Chen, Chunqi Lai, Qi Chen, Ge Zhang, Yongmei Jiang Tags: Research paper Source Type: research
An autologous tumor vaccine for CLL
(Source: Leukemia Research)
Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Fang Zhu, Ismat Khatri, David Spaner, Reginald M. Gorczynski Source Type: research
It is not just the number of metaphases that matters
We read with great interest the study of Swart et al. [1] entitled “ Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower −risk MDS” recently published and we would like to like to discuss three important ideas regarding these results: 1) It is not just the number of metaphases that matters; 2) Sequential Karyotype also ad ds information; 3) FISH really adds information but does not substitute G-Banding. (Source: Leukemia Research)
Source: Leukemia Research - March 1, 2018 Category: Hematology Authors: Mar ília Braga Costa, Daniela de Paula Borges, Mayara Magna de Lima Melo, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro Tags: Letter to the editor Source Type: research
It is not just the number of metaphases that matters
(Source: Leukemia Research)
Source: Leukemia Research - March 1, 2018 Category: Hematology Authors: Mar ília Braga Costa, Daniela de Paula Borges, Mayara Magna de Lima Melo, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro Tags: Letter to the Editor Source Type: research
Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients
We read with great interest the paper published by Ahmed et al. (September 27 issue) [1] who retrospectively reported 94 patients with acute myeloid leukemia (AML) undergoing induction chemotherapy who were transferred to the intensive care unit (ICU). In this paper, median overall survival (OS) was 1.3 month. ICU and hospital mortality (HM) were 61% and 71% respectively. Three and 6 months OS were 17% and 18% respectively. Acute respiratory failure (ARF) was the most common reason for ICU transfer (88%). (Source: Leukemia Research)
Source: Leukemia Research - February 28, 2018 Category: Hematology Authors: Colombe Saillard, Elodie Elkaim, Jerome Rey, Evelyne d ’Incan, Aude Charbonnier, Anne Etienne, Antoine Sannini, Laurent Chow-Chine, Magali Bisbal, Norbert Vey, Djamel Mokart Tags: Letter to the Editor Source Type: research
Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients
(Source: Leukemia Research)
Source: Leukemia Research - February 28, 2018 Category: Hematology Authors: Colombe Saillard, Elodie Elkaim, Jerome Rey, Evelyne d ’Incan, Aude Charbonnier, Anne Etienne, Antoine Sannini, Laurent Chow-Chine, Magali Bisbal, Norbert Vey, Djamel Mokart Tags: Letter to the Editor Source Type: research
ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation
AML1 is a transcription factor, which is expressed in hematopoietic tissues and essential for blood cell development by transactivating target genes known to be critical for myeloid differentiation and function [1]. The chromosomal translocation of transcription factor involving the t(8;21)(q22;q22) is the most frequently recurring cytogenetic abnormalitiy associated with AML, accounting for 10% –12% of AML patients [2,3]. The t(8;21) translocation results in the AML1-ETO fusion protein, which contains only the DNA binding domain of AML1 and almost the full length of ETO. (Source: Leukemia Research)
Source: Leukemia Research - February 27, 2018 Category: Hematology Authors: Jia Liu, Wenting Lu, Shuang Liu, Ying Wang, Saisai Li, Yingxi Xu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Jianxiang Wang Tags: Research paper Source Type: research
ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation
(Source: Leukemia Research)
Source: Leukemia Research - February 27, 2018 Category: Hematology Authors: Jia Liu, Wenting Lu, Shuang Liu, Ying Wang, Saisai Li, Yingxi Xu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Jianxiang Wang Tags: Research paper Source Type: research
Enhanced perforin expression associated with dasatinib therapy in natural killer cells
Dasatinib is a multikinase inhibitor approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Among various tyrosine kinase inhibitors (TKIs), dasatinib is the only one that acts by stimulating the normal immune response. Studies have shown that dasatinib rapidly induces an increase in the number of lymphocytes, particularly natural killer (NK) cells and/or cytotoxic T lymphocytes (CTLs), in the blood [1 –4]. These lymphocytes exhibit large granular lymphocyte (LGL) morphology and a differentiated immunophenotype [1–5]. (Source: Leukemia Research)
Source: Leukemia Research - February 24, 2018 Category: Hematology Authors: Noriyoshi Iriyama, Hiromichi Takahashi, Katsuhiro Miura, Yoshihito Uchino, Masaru Nakagawa, Yoshihiro Hatta, Masami Takei Tags: Research paper Source Type: research
Enhanced perforin expression associated with dasatinib therapy in natural killer cells
(Source: Leukemia Research)
Source: Leukemia Research - February 24, 2018 Category: Hematology Authors: Noriyoshi Iriyama, Hiromichi Takahashi, Katsuhiro Miura, Yoshihito Uchino, Masaru Nakagawa, Yoshihiro Hatta, Masami Takei Tags: Research paper Source Type: research
